These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 29156699)
1. Cell-specific regulation of proliferation by Ano1/TMEM16A in breast cancer with different ER, PR, and HER2 status. Wu H; Wang H; Guan S; Zhang J; Chen Q; Wang X; Ma K; Zhao P; Zhao H; Yao W; Jin F; Xiao Q; Wei M Oncotarget; 2017 Oct; 8(49):84996-85013. PubMed ID: 29156699 [TBL] [Abstract][Full Text] [Related]
2. Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment. Wu H; Guan S; Sun M; Yu Z; Zhao L; He M; Zhao H; Yao W; Wang E; Jin F; Xiao Q; Wei M PLoS One; 2015; 10(5):e0126128. PubMed ID: 25961581 [TBL] [Abstract][Full Text] [Related]
3. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Parise CA; Bauer KR; Brown MM; Caggiano V Breast J; 2009; 15(6):593-602. PubMed ID: 19764994 [TBL] [Abstract][Full Text] [Related]
4. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909 [TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study. Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431 [TBL] [Abstract][Full Text] [Related]
6. Prognostic role of progesterone receptor expression in a population-based analysis. Caldarella A; Barchielli A J Cancer Res Clin Oncol; 2017 Dec; 143(12):2505-2509. PubMed ID: 28889189 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002 [TBL] [Abstract][Full Text] [Related]
8. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542 [TBL] [Abstract][Full Text] [Related]
10. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. Penault-Llorca F; André F; Sagan C; Lacroix-Triki M; Denoux Y; Verriele V; Jacquemier J; Baranzelli MC; Bibeau F; Antoine M; Lagarde N; Martin AL; Asselain B; Roché H J Clin Oncol; 2009 Jun; 27(17):2809-15. PubMed ID: 19380452 [TBL] [Abstract][Full Text] [Related]
11. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers. Murase K; Yanai A; Saito M; Imamura M; Miyagawa Y; Takatsuka Y; Inoue N; Ito T; Hirota S; Sasa M; Katagiri T; Fujimoto Y; Hatada T; Ichii S; Nishizaki T; Tomita N; Miyoshi Y Breast Cancer; 2014 Jan; 21(1):52-7. PubMed ID: 22359195 [TBL] [Abstract][Full Text] [Related]
12. Alterations in three biomarkers (estrogen receptor, progesterone receptor and human epidermal growth factor 2) and the Ki67 index between primary and metastatic breast cancer lesions. Fujii K; Watanabe R; Ando T; Kousaka J; Mouri Y; Yoshida M; Imai T; Nakano S; Fukutomi T Biomed Rep; 2017 Dec; 7(6):535-542. PubMed ID: 29188058 [TBL] [Abstract][Full Text] [Related]
13. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043 [TBL] [Abstract][Full Text] [Related]
14. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187 [TBL] [Abstract][Full Text] [Related]
15. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey. Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D J BUON; 2013; 18(3):619-22. PubMed ID: 24065473 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237 [TBL] [Abstract][Full Text] [Related]
17. Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer. Bjerre C; Knoop A; Bjerre K; Larsen MS; Henriksen KL; Lyng MB; Ditzel HJ; Rasmussen BB; Brünner N; Ejlertsen B; Laenkholm AV Acta Oncol; 2013 Jan; 52(1):82-90. PubMed ID: 23205744 [TBL] [Abstract][Full Text] [Related]
18. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. Chapman JA; Sgroi DC; Goss PE; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Badovinac-Crnjevic T; Shepherd LE; Pollak MN Breast Cancer Res Treat; 2016 May; 157(1):101-8. PubMed ID: 27116182 [TBL] [Abstract][Full Text] [Related]
19. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients. Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283 [TBL] [Abstract][Full Text] [Related]
20. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010. García Fernández A; Giménez N; Fraile M; González S; Chabrera C; Torras M; González C; Salas A; Barco I; Cirera L; Cambra MJ; Veloso E; Pessarrodona A Breast; 2012 Jun; 21(3):366-73. PubMed ID: 22487206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]